RxDoctor Payments Data

Clois Slaughter, MD

Family Medicine · Lecompte, LANPI 1184627838

Payments from drug & device makers

$4,944in general payments, 2019–2025

Across 306 payments — averaging $16.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$781
  • Novo Nordisk$748
  • AstraZeneca$431
  • Lilly USA, LLC$411
  • Astellas Pharma US Inc$283
  • Pfizer$279
  • plus $2K from 24 others

What the payments were for

  • Food & beverage$4,86398%
  • Education$812%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,944 in reported general payments places this provider in the 80th percentile of 1,469 family medicine providers in Louisiana.

See all family medicine providers in Louisiana

Medicare billing

Part B allowed, 2024
$117,540
Medicare patients
442
Services billed
1,487

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide118$150,237
LinzessLinaclotide218$134,621
EliquisApixaban299$133,024
TrulicityDulaglutide100$103,479
MounjaroTirzepatide83$101,884
JardianceEmpagliflozin128$98,552
FarxigaDapagliflozin Propanediol88$78,534
JanuviaSitagliptin Phosphate90$69,538
Trelegy ElliptaFluticasone/Umeclidin/Vilanter61$62,189
MyrbetriqMirabegron70$39,741
CreonLipase/Protease/Amylase29$36,777
EntrestoSacubitril/Valsartan49$30,613
XareltoRivaroxaban47$20,553
MultaqDronedarone Hcl34$13,609
VascepaIcosapent Ethyl18$11,531

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$411$205,363183 claims
AbbVieLinzess, Creon, Restasis$781$180,291261 claims
Novo NordiskOzempic$748$150,237118 claims
PfizerEliquis$279$133,024299 claims
Boehringer IngelheimJardiance, Tradjenta, Stiolto Respimat$142$111,287153 claims
AstraZenecaFarxiga$431$78,53488 claims
GSKTrelegy Ellipta, Breo Ellipta$236$71,59284 claims
MerckJanuvia$180$69,53890 claims
Astellas Pharma US IncMyrbetriq$283$39,74170 claims
NovartisEntresto$40$30,61349 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 1,469 family medicine providers in Louisiana.

Other family medicine in Lecompte

See the full list for Louisiana

Where these figures come from

Is this you, or does something look wrong? →